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Abstract
Acetyl-CoA carboxylases ACC1 and ACC2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA, regulating fatty-acid
synthesis and oxidation, and are potential targets for treatment of metabolic syndrome. Expression of ACC1 in rodent
lipogenic tissues and ACC2 in rodent oxidative tissues, coupled with the predicted localization of ACC2 to the mitochondrial
membrane, have suggested separate functional roles for ACC1 in lipogenesis and ACC2 in fatty acid oxidation. We find,
however, that human adipose tissue, unlike rodent adipose, expresses more ACC2 mRNA relative to the oxidative tissues
muscle and heart. Human adipose, along with human liver, expresses more ACC2 than ACC1. Using RT-PCR, real-time PCR,
and immunoprecipitation we report a novel isoform of ACC2 (ACC2.v2) that is expressed at significant levels in human
adipose. The protein generated by this isoform has enzymatic activity, is endogenously expressed in adipose, and lacks the
N-terminal sequence. Both ACC2 isoforms are capable of de novo lipogenesis, suggesting that ACC2, in addition to ACC1,
may play a role in lipogenesis. The results demonstrate a significant difference in ACC expression between human and
rodents, which may introduce difficulties for the use of rodent models for development of ACC inhibitors.
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Introduction
Acetyl-CoA carboxylase alpha (ACC1) and beta (ACC2)
catalyze the carboxylation of acetyl-CoA to malonyl-CoA.
Malonyl-CoA is a substrate for fatty acid synthase and also
inhibits carnitine palmitoyltransferase-1, such that malonyl-CoA is
a key molecule regulating both the biosynthesis and oxidation of
fatty acids. Thus ACC1 and ACC2 are key regulators of the fatty-
acid synthesis and oxidation pathways [1–5].
In mammals, both of ACC1 and ACC2 are multifunctional
enzymes, containing biotin carboxyl carrier, biotin carboxylase,
and carboxyl transferase domains all within a single polypeptide
chain (Supplemental Figure S1). Although ACC1 and ACC2 share
over 70% protein sequence identity and have the same enzymatic
activity, they are believed to have distinct cellular roles. Indeed,
while mouse ACC1
2/2 mutants are embryonic lethal [6,7],
mutant ACC2
2/2 mice have a normal lifespan but higher fat
oxidation rate in muscle and adipose tissues and are resistant to
diet-induced obesity [8–10], observations which have made ACC2
an attractive target for treatment of obesity and type 2 diabetes
[7,11–13]. ACC1 is cytosolic and believed to be the primary
acetyl-CoA carboxylase (ACC) involved in de novo fatty-acid
synthesis. This is supported by observations of high ACC1
expression in rat and mouse lipogenic tissues [14,15]. In contrast,
ACC2 has been reported to regulate fatty-acid oxidation through
malonyl-CoA mediated inhibition of carnitine palmitoyltransfer-
ase-1 [14–19]. Physiological studies have also linked ACC2
expression in muscle to physical exercise, corroborating a link
between ACC2 and fatty-acid oxidation [20–22]. Immunofluo-
rescence microscopy studies suggest that ACC2 is preferentially
localized to the mitochondria, possibly due to the unique ,220
amino acid N-terminus of ACC2 [18]. This N-terminus includes a
leader sequence of ,20 hydrophobic residues that has been
hypothesized to be responsible for mitochondrial localization and
thus the functional difference between two genes [15].
Arguments against a lipogenic role for ACC2 are based
primarily on preferential expression of ACC2 in rodents within
non-lipogenic tissues. In rat, for example, ACC2 is expressed in
muscle, heart, liver, mammary gland, and brown adipose but was
not observed in white adipose [14,23]. In prior human expression
studies, ACC2 transcript levels were measured in eight tissues [15],
and the highest expression of ACC2 was observed in skeletal
muscle. However, ACC2 expression in human adipose tissue was
not assayed. In addition, EST sequence databases suggest the
existence of novel alternative splice forms [5].
Since ACC inhibition is a candidate treatment for human
metabolic syndrome, there is a clear need to characterize ACC
expression in human tissues. Here we present RNA and protein
evidence that ACC2 is expressed at higher levels in human white
adipose than in human skeletal muscle, and that the expression of
ACC2 in human white adipose is higher than that of ACC1.
Further, we show RNA and protein evidence for a second ACC2
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4369isoform that is expressed in human adipose, has enzymatic and de
novo lipogenic activity, is endogenously expressed, and has a
distinct N-terminus lacking the proposed N-terminal mitochon-
drial localization sequence. These observations suggest ACC2 may
play a role in fatty-acid synthesis, and that there may be molecular
differences in fat metabolism between rodents and humans.
Results
ACC2 mRNA is present at higher levels in human adipose
tissue than ACC1
Expression levels of ACC1 and ACC2 in human tissues, each
pooled from multiple donors, were examined using oligonucleotide
microarrays [24] and calibrated quantitative real-time RT-PCR
(Figure 1). Microarray data were derived from custom microarray
patterns, with probes placed in every exon and exon-exon
junction, and a random-priming amplification protocol (Materials
and Methods). Intensities for ACC1 and ACC2 are the average of
over 100 probes per gene. In the tissues examined, ACC1 is
expressed at higher levels than ACC2 in brain, prostate, and
ovary, whereas ACC2 is expressed at higher levels in adipose,
mammary gland, muscle, heart, gastrointestinal tissues, liver,
kidney, thyroid, pituitary, and adrenal gland.
We validated these results using calibrated real-time RT-PCR
(Taqman). Calibrated Taqman involves construction of a standard
curve derived from dilution series measurements, resulting in
highly quantitative measurements permitting cross-gene and cross-
tissue comparisons. We find the relative expression of ACC1 and
ACC2 transcripts measured by microarray and quantitative PCR
(Figure 1, inset) are in good agreement. Both datasets clearly show
that ACC2 is strongly expressed in adipose tissue, at levels greater
than in muscle.
A transcript variant of ACC2 with a novel N-terminus
When mapped to the human genome, three human and mouse
ESTs, human CA392208 and mouse BB854145 and BB866065,
suggest the existence of an additional transcribed region between
the first and second exons of the RefSeq ACC2 isoform (ACC2.v1)
NM_001093 (Figure 2A). Other genomic data support this
interpretation, including a candidate ATG start codon, high
human, rodent and chicken sequence conservation, and the
absence of termination codons (Figure 2A, Figure S2). Usage of
this ATG codon as start site could generate an in-frame ACC2
protein in which the first 218 amino acids of the known RefSeq
protein NP_001084, including the hydrophobic N-terminus, were
replaced with a novel 16 amino-acid N-terminus (Figure 2B). This
variant, referred to in what follows as ACC2.v2, is less likely to
encode a membrane-associated protein because it lacks the
putative mitochondrial localization sequence.
The novel ACC2.v2 transcript is expressed in white
adipose
To validate transcription of this computational prediction, we
designed RT-PCR primers from the novel exon 1 to the known
exon 5. The result shows clear expression of the novel band in
several tissues (Figure 2A). Cloning followed by sequencing of this
band confirmed the sequence identity, which has been deposited
in dbEST as EH093926. This sequence cannot be mapped to any
other region of the human genome, including the ACC1 locus,
and thus experimentally confirms ACC2.v2 transcription.
Figure 1. Human ACC1 and ACC2 mRNA expression from microarray and TaqMan (inset) measurements. Microarray data show the
average probe intensity from 113 (ACC1) and 120 (ACC2) probes and are ordered based on ACC1 expression. Calibrated TaqMan data were scaled to
a maximum of 100.
doi:10.1371/journal.pone.0004369.g001
ACC2 Isoforms and Expression
PLoS ONE | www.plosone.org 2 February 2009 | Volume 4 | Issue 2 | e4369Expression of ACC1 and ACC2 isoforms in human, rat,
and mouse tissues
The relative abundances of ACC1, ACC2.v1 and ACC2.v2
transcripts were measured in five human tissues using calibrated
real-time RT-PCR. As shown in Figure 3 (top), the human
ACC2.v2 transcript is less abundant than the known isoform but is
significantly expressed in all five tissues tested. The highest
absolute expression level of ACC2.v2 is observed in adipose tissue,
where the splice variant accounts for over 20% of ACC2
expression, at levels comparable to ACC1 expression. We also
measured the levels of ACC1, ACC2.v1, and ACC2.v2 in
corresponding mouse and rat tissues (Figures 3, middle and
lower). The ratio of ACC1 and ACC2 expression is dramatically
different between rodent tissues and human tissues, particularly in
the lipogenic tissues adipose and liver. Unlike human tissues, both
rat and mouse adipose express ACC2 at low levels, significantly
lower than ACC1, and rodent liver contains more ACC1 than
ACC2. Furthermore, rodent muscle expresses ACC2 at levels
much higher than seen in rodent adipose, different from the
pattern in humans. Finally, the ratio of ACC2.v1 to ACC2.v2
transcript expression is similar in rodent and human tissues,
further suggesting that the novel ACC2.v2 product is regulated
and may be functional.
ACC1 and ACC2 protein expression in human, rat, and
mouse tissue
To determine if these transcript expression patterns reflected
enzyme levels, we assayed ACC1 and ACC2 protein levels by
Westernblot usingstreptavidinand antibodies specifictothe middle
of ACC1 and to the N terminus of ACC2.v1 (Figure 4). A single
biotin molecule covalently couples to a single ACC molecule,
permitting qualitative determination of ACC1 and ACC2 protein
expression with streptavidin-HRP (anti-biotin). A bright ACC2
band was observed in the human muscle sample (first column). The
three human adipose samples probedall show ACC2 bands and less
intense ACC1 bands. Human, rat, and mouse liver showed a mix of
ACC1 and ACC2. Rat and mouse white adipose show intensities at
the ACC1 band and lower intensities at the ACC2 band. These
results, while highly qualitative, suggest that the ACC2 protein is
endogenously expressed in human adipose. We also find evidence
Figure 2. Novel ACC2 isoform. (A) Genomic alignment of the 59 end of RefSeq transcript NM_001093, human EST CA392208 (exons are shown as
boxes), ‘FirstExon’ predictions [33], including the CpG island, promoter region, and first exon location, and conservation score for human, mouse, rat,
and chicken [34]. The green and red boxes in the top two rows are the alternative first exons. The vertical, dashed blue line in the zoomed image
(lower left panel) shows the predicted start ATG codon. The gel image using RT-PCR primers in novel exon 1 and known exon 5 shows intensity in all
tissues tested at the predicted size. (B) The RNA sequence of the novel exon 1 (red), the start of exon 2 (black), and the predicted protein. The first
base is the beginning of the aligned mouse EST BB866065. The RT-PCR primer target sequence is underlined.
doi:10.1371/journal.pone.0004369.g002
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(Supplemental Figure S3).
ACC2.v2, ACC2.v1, and ACC1 protein activity
To confirm the ACC2.v2 transcript isoform generates protein,
we cloned ACC2.v2 and ACC2.v1 and overexpressed them in
FM3A cells, a mammary carcinoma-derived cell line. Recombi-
nant ACC2.v2 and ACC2.v1 were detected at expected molecular
weights of ,255 and ,277 kDa, respectively and biotinylated in
Western blotting (Figure 5A). We investigated ACC enzymological
properties using the in vitro
14CO2 fixation assay using lysate from
FM3A cells. Overexpression of either ACC2.v2 or ACC2.v1
increases ACC enzymatic activity .20-fold relative to vector alone
(Figure 5B). Using purified recombinant human ACC1, ACC2.v1
and ACC2.v2, we found Km values for acetyl-CoA, CO2 and ATP
Figure 3. Expression of ACC1 and ACC2 mRNA isoforms in human, mouse, and rat tissues. TaqMan probes were designed to specifically
monitor each transcript and were calibrated using standard curves (see Methods). Expression levels were scaled for each species such that the
maximum ACC1 or total ACC2 expression (ACC2.v1 plus ACC2.v2) is 100.
doi:10.1371/journal.pone.0004369.g003
Figure 4. ACC protein expression, measured with three different antibodies: ACC1+ACC2 (top row), ACC1-specific (middle row),
and ACC2.v1-specific (bottom row). Each human adipose and liver sample is from a different individual. Streptavidin targets an endogenous
biotin molecule within each ACC isoforms, so its intensity reflects molar ratio of each ACC isoform. The ACC2.v1 antibody specifically targets the
ACC2.v1 N-terminus and does not detect ACC2.v2 protein.
doi:10.1371/journal.pone.0004369.g004
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between 51 and 110 mM; for ATP between 44 and 110 mM; and
for NaHCO3 between 2.9 and 6.5 mM (Table 1). Relative to
ACC2.v1, ACC2.v2 showed 2 to 3-fold increases in Km values for
ACC2.v2 with respect to ATP and NaHCO3. Finally, we assayed
de novo lipogenesis (DNL) activity in FM3A cells overexpressing
recombinant ACC clones using [
14C]acetate incorporation as a
marker for DNL (Figure 5C). After overexpression, incorporation
was first measured in the presence of a non-specific ACC inhibitor,
labeled ‘compound A,’ as a control, and then without inhibitor.
Overexpression of ACC1 increased cellular DNL activity almost
4-fold relative to vector alone. Cells expressing either ACC2.v2 or
ACC2.v1 showed an approximately 2-fold relative increase in
DNL.
Discussion
Our measurements of ACC1 and ACC2 transcript levels in
rodent samples agree with published data [14,23] showing high
levels of ACC1 in adipose, high levels of ACC2 in heart and
skeletal muscle tissues, and higher levels of ACC1 than ACC2 in
Figure 5. Expression and activities of ACC2 proteins. (A) Expression of recombinant ACC2.v1 and ACC2.v2 proteins in FM3A cells. Recombinant
ACC proteins in cell lysates from FM3A cells overexpressing ACC isoforms were detected by Western blotting. Arrows mark the locations of ACC2.V1,
ACC1, and ACC2.v2, from top to bottom. (B) ACC activities of recombinant ACC2.v1 and ACC2.v2 protein. ACC activities in FM3A cell lysates were
measured by an in vitro
14CO2 fixation assay, measuring the incorporation of [
14C]bicarbonate into [
14C]malonyl-CoA. (C) DNL activity in FM3A cells
overexpressing recombinant ACCs. DNL activities were measured as incorporated radio activities of [
14C]acetate into cells in the presence of
Simvastatin, a HMG-CoA reductase inhibitor. The non-specific[
14C]acetate incorporation was determined in the presence of 10 mM a specific dual
ACC1 and ACC2 inhibitor, labeled ‘compound A,’ and subtracted from total DNL activity in each FM3A clone.
doi:10.1371/journal.pone.0004369.g005
Table 1. Km values.
Km (mM)
Acetyl-CoA ATP NaHCO3
hACC1 51635 4 65 65006533
hACC2.v1 110613 4464 29006193
hACC2.v2 94613 11067 65006556
doi:10.1371/journal.pone.0004369.t001
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profiling of mouse brown adipose shows higher ACC2 expression
than in mouse white adipose (data not shown). Human tissues
show a very different expression pattern (Figure 1). Human
adipose expresses ACC2 at levels four times higher than ACC1, a
higher level than observed in human skeletal muscle. Human liver
expresses more ACC2 than ACC1. Although ACC2 was first
cloned from human adipose tissue [25], attention has focused on
the role of ACC2 in fatty-acid oxidation in muscle tissue, and, to
our knowledge, the high expression of ACC2 in human adipose
has not previously been reported. Furthermore, microarray
expression profiling in 53 dog and 65 rhesus monkey tissues (data
not shown) show highest ACC2 levels in dog and rhesus adipose.
Thus, ACC2 expression in primate and canine adipose is different
than in rodent adipose, and may represent a species difference in
fatty-acid regulation.
Although we have shown there are significant differences in
ACC2 transcript and protein expression between rodent and
human tissues, we cannot rule out the possibility that a part of the
observed differences is due to variation in tissue dissection, RNA
isolation, or sample pooling. However, adipose is a relatively
homogeneous tissue, such that different dissection methods would
not be expected to produce large changes in the cell-type
composition of the isolated adipose tissue. Secondly, adipose
samples collected from multiple vendors, for both individuals and
pools of individuals, consistently show similar mRNA expression
profiles that cluster together in a background of hundreds of other
tissue samples (data not shown), suggesting that dissection and
RNA isolation differences tend to produce relatively small effects
on mRNA profiles.
We demonstrate the existence of a novel ACC2 isoform
(ACC2.v2) that is expressed in human white adipose tissue and
has enzymatic and DNL activity. The protein is smaller
(,255 kDa) than that of ACC1 (,265 kDa) and the known
ACC2 protein (ACC2.v1, ,277 kDa) (Figure 5A, Supplemental
Figures S1, S3). This form lacks the hydrophobic N-terminus
found in the known ACC2 isoform, including the putative
mitochondrial localization sequence but has all three catalytic
domains essential for ACC enzyme activity. The ACC2.v2 mRNA
accounts for the majority of ACC2 transcripts in testis, over 20%
in adipose and approximately 5% in skeletal muscle. ACC2.v2 is
also found in mouse and rat and is expressed at ratios similar to
ACC2.v1 in these species (Figure 3), suggesting that the novel
isoform is similarly regulated between species.
In human adipose, over 20% of the highly expressed ACC2
mRNA is in the form of ACC2.v2, which is expressed at levels
comparable to ACC1. ACC2.v2 and ACC1 transcripts encode
proteins that are 76% identical (87% similar), and the biotin
carboxylation and carboxyl transferase regions are 84% and 81%
identical (93% and 91% similar), respectively. The lack of the first
coding exon of ACC2.v1 makes the ACC2.v2 protein sequence
more similar to ACC1. Previous enzyme kinetics show only lower
Km for ACC1 than for ACC2 for acetyl-CoA and citrate [16], and
our data suggest ACC2.v1 and ACC2.v2 have comparable ACC
activity. All recombinant ACC isoforms tested, ACC1, ACC2.v1,
and ACC2.v2, showed DNL activity in cells. However, given the
moderate DNL activity of ACC2.v2 despite its level of protein
expression, ACC2.v2 may not be as efficiently coupled to DNL
pathway as ACC1. While cellular activity is also dependent on
mRNA translational rates and phosphorylation states [23,26–28],
these expression and enzymatic and DNL activity results suggest
that ACC2 isoforms, both ACC2.v1 and ACC2.v2, are capable of
contributing to fatty-acid synthesis in human adipose tissue. This
hypothesis would also help explain the observation that liver-
specific ACC1 deficient mice showed hepatic DNL [7], and is
consistent with the observation by Oh et al. [9] that ACC2
2/2
mice showed not only increased fatty-acid oxidation but also
decreased fat levels in adipose. Finally, our results also suggest
ACC2 specific inhibition could result in different physiological
effects in humans than in rodents.
Materials and Methods
Microarray data
Custom oligonucleotide microarrays were purchased from
Agilent Technologies (Palo Alto, California). We designed these
arrays to monitor the expression of 18,000 genes and associated
alternate splicing events [29]. After alignment of 107,551 full-
length human mRNA transcripts to the human genome, probes
were designed to target every exon (60 mers) and every exon-exon
junction (36 mers on 10 nucleotide T stilts) [24]. Poly[A]
+ mRNA
was amplified with a full-length amplification method using
random-priming sequences to reproduce the entire transcript
[24]. Fluorescent dye-labeling, hybridization conditions, and
scanning were performed as previously [30]. Each amplified
sample was hybridized twice against a common reference pool in a
dye-swap experiment. Intensities shown are the mean of all probes
for each transcript (113 for ACC1 and 120 for ACC2), after
normalization using a common reference pool. Error bars estimate
measurement error and not biological variation.
Tissue samples
Human tissues and cell line samples were purchased as mRNA
or total RNA (Clontech, Mountain View, California). Each tissue
sample was pooled from multiple donors, typically 12. Human
adipose tissue consisted of subcutaneous epithelial white adipose
tissue. Mouse and rat tissues were purchased from Biochain
(Hayward, California) and Clontech. Human protein samples
were purchased from Biochain and Biopredic International
(Rennes, France) as tissue lysate or frozen block, Male Sprague-
Dawley rats from Japan SLC, (Hamamatsu, Japan) and
C57Black/6J mice from CLEA Japan (Tokyo, Japan).
Genomic analyses
Alignments to the human genome (NCBI Build 34, USCS hg16)
were done with sim4 [31] for human ESTs and EST_GENOME
[32] for mouse ESTs. FirstExon predictions [33] and human/
mouse/rat/chicken conservation scores [34] were downloaded
from UCSC genomic databases [35].
RT-PCR
Supplemental Table S1 lists the RT-PCR primer sequences to
monitor the known and novel first exons of ACC2. Reverse
transcription-polymerase chain reaction (RT-PCR) amplification
from tissue-specific mRNA or total RNA was performed as
previously described [29]. The oligonucleotides were obtained
from Qiagen (Valencia, California). Amplicons were subcloned
into pCR2.1 using a TOPO-TA cloning kit (Invitrogen Corp.,
Carlsbad, California). Sequencing was performed by a commercial
vendor (Lark Technologies Inc., Houston, Texas).
Quantitative PCR
TaqMan primer and probe sequences used to monitor ACC1,
ACC2.v1, and ACC2.v2 levels quantitatively in human and mouse
tissues are shown in Supplemental Table S1. ACC2.v1 is the
isoform defined by transcript NM_001093 and ACC2.v2 is the
novel isoform defined here. TaqMan primer-probe reagents were
obtained through the Applied Biosystems Assays-by-Design
ACC2 Isoforms and Expression
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designed to straddle a unique splice junction characteristic of each
alternative splice form. TaqMan assays were performed on an ABI
7900 real time PCR instrument in 10 ml assays that were run in
triplicate in a 384-well format optical PCR plate. The assays were
calibrated with isoform-specific RT-PCR clones using the
standard curve method [36]. Standard curves generated from
plasmid clones were linear across at least six orders of magnitude,
and all reported values derived for total tissue RNA fell within the
range of these standard curves. RNA was converted to cDNA for
TaqMan measurements using a commercially available kit from
Applied Biosystems. All assays were normalized on a tissue-to-
tissue basis by adding a constant amount of input total RNA into
the RT reaction.
Western blotting
Total protein samples were separated using 3–8% Tris-Acetate
polyacrylamide gel electrophoresis (Invitrogen), and then trans-
ferred to PVDF membrane (Immobilon-P, Millipore, Billerica,
Massachusetts). Membranes were blocked with Block Ace reagent
(Dainippon Sumitomo Pharma Co., Ltd, Osaka, Japan/Snow
Brand Milk Product Co. Ltd, Tokyo, Japan), and then incubated
with HRP-conjugated streptavidin (Zymed Laboratories, South
San Francisco, CA) or corresponding polyclonal antibodies
followed by HRP-conjugated 2nd antibody according to the
manufacturers (Pierce Biotechnology, Inc., Rockford, IL). Anti-
body dilutions are shown in Supplemental Table S2. Chemilumi-
nescent detection was performed using SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce) and LAS-3000 lumines-
cent image analyzer (FUJIFILM Corp., Tokyo, Japan). Polyclonal
antibodies specific for ACC1, ACC2.v1 and ACC2.v2 were
prepared by immunizing of polypeptides, shown in Supplemental
Table S2, to New Zealand white rabbits. The anti-ACC2.v1
antibody was raised with N-terminal peptide for ACC2.v1 but not
for ACC2.v2 (Supplemental Table S2).
Cloning and expression
The full-length human ACC2.v1 cDNA was amplified by PCR
from human skeletal muscle Marathon-Ready cDNA (Clontech) was
used as the template using the following primer pair: forward, 59-
GCCTAGGTAATGGTCTTGCTTCTTTGTCTATCTTGTC-
TG-39; reverse, 59-ACCGGTGGTGGAGGCCGGGCTGTC-
CATG-39. The amplified product was cloned into a pcDNA5/
FRT/V5-His-TOPO vector (Invitrogen) with an added V5 epitope
and His tags at the C-terminus, and was confirmed by sequencing.
The plasmid was then digested with AvrII and PmeI, and the cDNA
fragment was subcloned into the SpeI/EcoRV site of pEFcDNA3
(Invitrogen) vector. The ACC2.v2 cDNA was prepared by
replacement of the ACC2.v1 specific N-terminus with that of
ACC2.v2 by PCR using the ACC2.v1 cDNA as a template and the
following primer pair: forward, 59-GCCTAGGTAATGAG-
TCCTGCCAAGTGCAAGATCTGTTTCCCTGATCGCGAA-
GTAAAGCCGAGCATGTCGGGACTCCA-39, reverse, 59-
GGCCGGTGCTTCCTCAAC 39. The PCR product was then
digested with AvrII/HindIII and exchanged with that of ACC2.v1
cDNA to construct a full-length ACC2.v2 cDNA clone. The
ACC2.v1 and ACC2.v2 expression plasmids and pEFcDNA3 vector
were introduced into FM3A (mouse mammary carcinoma) cells
(RIKEN cell bank, #RCB0086) using Lipofectaimine 2000 (Invitro-
gen) or Effectene Transfection Reagent (Qiagen, Hilden, Germany),
according to manufacturers’ instructions. The FM3A cells were
cultured in RPMI 1640 medium (Invitrogen) containing 10% fetal
bovine serum (HyClone, Logan, UT) and 1 mg/ml G418 (Invitro-
gen) at 37uCi n5 %C O 2, 95% air to obtain stable transfectants. Cell
lysate was prepared and subjected to ACC enzyme assay and
Western blot analysis.
Immunoprecipitation
The lysate of human adipose tissue was incubated with affinity-
purified anti-ACC2.v2 antibody for 3 hours at 4uC. After adding
Protein-A-agarose (Upstate, Charlottesville, VA), the incubation
was continued for an additional hour. ACC protein in supernatant
was precipitated by 35% saturated ammonium sulfate. The
immunoprecipitate and precipitated supernatant were subject to
Western blot analysis. Recombinant ACC2.v2 protein was added
to the immunoprecipitation reaction as a marker of migration
distance. The recombinant ACC2.v2 protein was expressed in
FM3A cells and purified with HiTrap chelating column (GE
Healthcare Piscataway, NJ).
ACC enzyme assay
ACC activity was measured with a standard
14CO2 fixation
assay which measures the incorporation of [
14C]bicarbonate into
[
14C]malonyl-CoA with a 96-well plate format. Recombinant
protein was incubated at 37uC for 40 minutes in a reaction
mixture consisting of 50 mM HEPES (pH 7.5), 2 mM DTT,
20 mM MgCl2, 20 mM citrate, 4 mM acetyl-CoA, 5 mM ATP,
4 mM NaHCO3, and 0.08 mM [
14C]NaHCO3 (50–62 mCi/
mmol, GE Healthcare) at 80 ml/well, and the reaction was
terminated by the addition of 20 ml 1 N HC1. Following
evaporation of unreacted [
14C]NaHCO3, radioactivity in the
residue was measured with TopCount Microplate scintillation
counter (PerkinElmer Inc., Wellesley, MA). For kinetic studies, the
reaction was run at acetyl-CoA, ATP and NaHCO3 ranging from
3.9 to 2,000 mM, 8.7 to 5,000 mM and 80 to 8,080 mM,
respectively. Km values were determined by non-linear regression
analysis of initial velocities, according to the standard Michaelis-
Menten equation.
Preparation of purified recombinant proteins
The FM3A cells expressing ACC2.v1 and ACC2.v2 were
cultured in RPMI 1640, 10% fetal bovine serum, penicillin/
streptomycin, and 0.5 mg/ml G418 at 37u C. and 5% CO2. The
Sf9 cells were grown in Grace’s Insect Cell Culture Medium
(Invitrogen, Carlsbad, Calif.) containing 10% fetal bovine serum,
0.1 mg/ml kanamycin, and 0.1% PLURONICH F-68 (Invitrogen,
Carlsbad, Calif.) at 30u C and 5% CO2. Sf9 cells were collected by
centrifugation and resuspended in the culture media at a cell
density of 1610
7 cells/ml. The Sf9 cells were then incubated with
the ACC1 expression virus stock solution (moi=approximately 5)
for 1 hour at room temperature. The infected Sf9 cells were
diluted with the culture media to cell density of 1610
6 cells, and
then cultured for 3 days. The recombinant ACC proteins were
purified with HiTrap chelating column (GE Healthcare Piscat-
away, NJ).
De novo lipogenesis (DNL)
DNL activity in FM3A cells was determined by whole-cell
incorporation of [
14C]acetate into the lipids. FM3A cells were
suspended in culture medium (RPMI1640+10% FBS containing
5 mM MEM sodium pyruvate and 1 mM Simvastatin, a HMG-
CoA reductase inhibitor) in at the density of 0.1610
6 cell/50 ml
and incubated at 37uC for 1 hour. After the incubation, 50 mlo f
culture medium were added to the cells and incubated another
1 hour in the presence or absence of 10 mM of a specific dual
ACC1 and ACC2 inhibitor, labeled ‘‘compound A’’. 18.5 kBq of
[2-
14C]acetate (2.07 GBq/mmol; GE Healthcare UK Ltd.) in
ACC2 Isoforms and Expression
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were incubated for additional 1 hour. At the end of the
incubation, cells were harvested onto 96 well Unifilter GF/C
(PerkinElmer, Inc.) using Unifilter 96 Harvester and washed with
4 times with ice-cold PBS
22. After dry up of the plate, 30 ml/well
of MicroScint 0 scintillant (PerkinElmer, Inc.) were added to the
plate and then radioactivity in the insoluble lipid fraction were
counted by TopCount Microplate scintillation counter (PerkinEl-
mer, Inc.).
Supporting Information
Figure S1 Domains in the ACC protein structure [37], including
the novel ACC2 isoform characterized here.
Found at: doi:10.1371/journal.pone.0004369.s001 (0.03 MB PPT)
Figure S2 Alignment of the rat and human genomes at the novel
exon and the start of the second exon (italics). There are no inserts
or deletions after the ‘ATG’ start codon (purple) but many before
this start site, suggesting that the protein (underlined) does not
extend in the upstream direction of this ATG.
Found at: doi:10.1371/journal.pone.0004369.s002 (0.02 MB PPT)
Figure S3 Detection of endogenous ACC2.v2 protein in human
adipose samples. Supernatant and immunoprecipitate from a
human adipose lysate was probed with streptavidin (anti-biotin)
and with an anti-ACC2.v2 antibody (Supplemental Table 1)
(columns A and B). The supernatant probed with streptavidin
shows a band at the expected ACC2.v1 location and at the
ACC1/ACC2.v2 location (column A, upper). The immunopre-
cipitate probed with the ACC2.v2-specific antibody (column B,
lower) shows a band at the predicted ACC.v2 location, suggestive
of endogenous ACC2.v2 protein expression. Columns C and D
repeat the experiment after adding recombinant ACC2.v2 protein.
The band location in the lower C and D panels marks the
ACC2.v2 migration distance. Arrows indicate the predicted
ACC2.v1, ACC1, and ACC2.v2 locations (top to bottom,
respectively).
Found at: doi:10.1371/journal.pone.0004369.s003 (0.23 MB PPT)
Table S1 TaqMan probe sequences
Found at: doi:10.1371/journal.pone.0004369.s004 (0.04 MB
DOC)
Table S2 Antibodies used
Found at: doi:10.1371/journal.pone.0004369.s005 (0.03 MB
DOC)
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